UTHR vs PKX Comparison

United Therapeutics Corp specializes in drug development for pulmonary arterial hypertension (PAH), a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. The company markets and sells the following commercial therapies in the United States to treat PAH: Tyvaso DPI (treprostinil) Inhalation Powder, Remodulin Injection, Orenitram (treprostinil) Extended-Release Tablets, Adcirca (tadalafil) Tablets, and Unituxin. It derives maximum revenue from the sale of Tyvaso DPI. Geographically, the company operates in United States and Rest of the World, of which United States generates majority of the revenue.

POSCO Holdings Inc is a holding company operating through its subsidiaries. Its business is divided into segments, with the Steel segment generating the majority of revenue from the manufacture and sale of steel products. The Infrastructure segment includes trading, construction, and logistics and system integration activities. The Rechargeable Battery Materials segment focuses on EV battery materials such as lithium, nickel, and cathode and anode materials. The Others segment includes the controlling company and investment business. Geographically, the Group generates majority of its revenue from Asia (excluding China and Japan).